Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
TurboFil Packaging Machines LLC, an equipment specialist dedicated solely to the design and development of liquid filling and assembly machines, has been named an official US sales & service representative for UK-based Sewtec Automation, which manufacturers packaging and other end-of-line equipment.
read more
I Holland, a manufacturer of tablet tooling for the pharmaceutical and nutraceutical markets, will be hosting a free webinar on 23 February 2022 which will focus on the importance of tool organisation and why it can improve tablet productivity.
read more
Senores Pharmaceuticals, Inc. announced the launch of Mexiletine Hydrochloride Capsules USP, 150 mg, 200 mg and 250 mg, a therapeutic equivalent version of MEXITIL (Mexiletine Hydrochloride) with one of the top 5 generic pharmaceutical companies in the U.S. market.
read more
AcelRx Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings, today announced the publication of an article reviewing the use of sufentanil sublingual tablet
read more
Lilly Canada announced that Health Canada has authorized Verzenio® (abemaciclib) (tablets), in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on ...
read more
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA).
Based on top-line efficacy ...
read more
The North America nutraceuticals market is expected to grow at a CAGR of around 6.6% during 2021-2027.
read more
Allied Market Research published a report, titled, "Pharmaceutical Primary Packaging Label Market that says the global pharmaceutical primary packaging label industry generated $2.37 billion in 2020, and is expected to reach $4.76 billion by 2030, witnessing a CAGR of 7.2% from 2021 to 2030.
read more
UK-based medical packaging equipment specialist Shawpak has introduced a 4-Side Seal (4SS) Pouch Machine. Designed for the packaging of flat medical products.
read more
Vifor Pharma Group appointed acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Oliver P. Kronenberg as members of the Vifor Pharma Executive Committee.
read more
Procaps Group, an integrated LatAm healthcare and pharmaceutical conglomerate, announced an expansion plan in the United States and Colombia for its Funtrition business through a new gummy manufacturing facility for nutraceutical and specialized gummy products.
read more
AB Biotek – a global business division of Associated British Foods plc – recently unveiled a new product in its human nutrition and health range focused on immune health. Supported by a newly published clinical study in December 2021, ABB C1 ImmunoEssentials offers consumers trained immunity, a relatively new term utilized within the industry.
read more
In early 2022, Titanium Dioxide will be banned as a food additive in the EU, with additional regulations expected in other regions. Designed as a replacement for coatings containing TiO2, VIVACOAT® free offers customized solutions for both white and dark tablet cores.
read more
APNAR Pharma LP (APNAR), headquartered in Chino, CA, has acquired East Windsor, NJ-based Aurex Laboratories (Aurex) for an undisclosed amount.
read more
Ascletis Pharma Inc. announced the approval of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
read more